EMA/650681/2013

European Medicines Agency decision

P/0278/2013

of 31 October 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for idelalisib (EMEA-001350-PIP02-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

European Medicines Agency decision

P/0278/2013

of 31 October 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for idelalisib (EMEA-001350-PIP02-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Gilead Sciences International Limited on 15 February 2013 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 October 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for idelalisib, film-coated tablet, age-appropriate solid oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for idelalisib, film-coated tablet, age-appropriate solid oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for idelalisib, film-coated tablet, age-appropriate solid oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Gilead Sciences International Limited, Flowers Building, Granta Park, Abington, CB21 6GT – Cambridge, United Kingdom.

Done at London, 31 October 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/618096/2013

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001350-PIP02-13

Scope of the application

Active substance(s):

Idelalisib

Condition(s):

Treatment of mature B-cell neoplasm

Pharmaceutical form(s):

Film-coated tablet
Age-appropriate solid oral formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Gilead Sciences International Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Gilead Sciences International Limited submitted for agreement to the European Medicines Agency on 15 February 2013 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 20 March 2013.

Supplementary information was provided by the applicant on 22 July 2013. The applicant proposed modifications to the paediatric investigation plan.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 11 October 2013

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of mature B-cell neoplasm

The waiver applies to:

- All paediatric patients from birth to less than 1 year of age;
- for film-coated tablets, for oral use, and for age-appropriate formulation, for oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: Treatment of mature B-cell neoplasm

2.1.1. Indication(s) targeted by the PIP

Treatment of children from 1 year to less than 18 years of age with a relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mediastinal B-cell lymphoma (MBCL) or Burkitt lymphoma.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet.

Age-appropriate solid oral formulation.

2.1.4. Measures

Area	Number of measures	Description
Quality	1	**Measure 1:** Development of an age-appropriate solid oral formulation.
Non-clinical	2	**Measure 2:** In-vitro activity study in paediatric lymphoma cells. **Measure 3:** In-vitro study in primary patient samples.
Clinical	3	**Measure 4:** Open-label, nonrandomised, multi-centre, multiple dose trial to evaluate pharmacokinetics and tolerability of idelalisib in children from 1 to less than 18 years of age with a relapsed or refractory mature B-cell neoplasm.

Area	Number of measures	Description
		Measure 5: Randomised, multi-centre, placebo controlled trial to evaluate safety and efficacy of idelalisib in combination with standard of care multi-agent anti-tumour chemotherapy in children from 1 to less than 18 years of age with a relapsed or refractory mature B-cell neoplasm.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2021
Deferral for one or more measures contained in the paediatric investigation plan:	Yes